(NASDAQ:KAYLA) KALA PHARMACEUTICALS INC. shares are trending up this morning at .74 cents on more than 2,000 trades. Light volume

(NASDAQ:KAYLA) KALA PHARMACEUTICALS INC. shares are trending up this morning at .74 cents on more than 2,000 trades. Light volume

Kala Announces Entry into Definitive Agreement To Sell EYSUVIS® And INVELTYS® To Alcon Inc.

–Kala Will Receive $60 Million in Upfront Payment; Eligible to Receive Additional Sales-Based Milestone Payments–
–Kala Will Focus Resources on Phase 2/3 Trial of KPI-012 for Orphan Disease Persistent Corneal Epithelial Defect–

ARLINGTON, Mass., May 23, 2022 (GLOBE NEWSWIRE) — Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has entered into a definitive agreement to sell its commercial portfolio and related intellectual property assets to Alcon Inc. This includes EYSUVIS, the first and only U.S. Food and Drug Administration (FDA) approved medicine for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease, and INVELTYS, a twice-a-day corticosteroid for the treatment of post-operative inflammation and pain following ocular surgery.

“The sale of EYSUVIS and INVELTYS is an important step as we execute on our strategic plan and pursue our mission of delivering innovative therapies that can address significant unmet needs in ophthalmology,” said Mark Iwicki, Chief Executive Officer and Chairman of Kala. “Alcon is an ideal partner to expand the reach of our commercial assets. Alcon has a decades-long history of delivering market-leading vision care to patients around the world and benefits from robust franchises in dry eye disease and surgical care, making them deeply familiar with eye care professionals and the patients EYSUVIS and INVELTYS are intended to treat. We look forward to working with Alcon through this transition and, ultimately, to devoting our internal resources to developing innovative therapies, including KPI-012, to further transform the treatment of eye diseases.”

Signup today for free and be the first to get notified of breaking news.

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist